TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...

President Donald J. Trump just released his second executive order (EO) addressing high prescription drug prices. This is ...

The pharmaceutical company AstraZeneca has filed a federal lawsuit against Utah Attorney General Derek Brown and Utah ...

With a focus on leveraging digital tools to build scalable platforms, the company supports projects that combine innovation, sustainability, and mass-market utility.

Pharmaceutical giant AstraZeneca is suing Utah’s attorney general and insurance commissioner over a law passed during the ...

Harvey Jones picks out five FTSE 100 companies that he believes could form the building blocks of a well-diversified Stocks and Shares ISA. The post FTSE 100 shares to consider buying for a well ...

New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could change lives for thousands of Australians.